
AbbVie to Acquire Arizona Manufacturing Facility
AbbVie will acquire West Pharmaceutical Services’ Tempe, Arizona, manufacturing facility for over $175 million to expand US drug delivery device capacity, with closing expected mid-2026.

AbbVie will acquire West Pharmaceutical Services’ Tempe, Arizona, manufacturing facility for over $175 million to expand US drug delivery device capacity, with closing expected mid-2026.

The investment will focus on developing gelatin and HPMC facilities, creating over 200 new jobs, and strengthening ACG’s 25-year presence in the US, with operations expected to begin in early 2027.

Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.

New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.

AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.

The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.

Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.


